Core Viewpoint - Midea Group, through its subsidiary Beijing Wandong Medical, has launched the Wandong DR Intelligent System, which aims to automate the entire imaging workflow, enhancing efficiency and accuracy in clinical diagnostics [1] Group 1: Product Development - The Wandong DR Intelligent System integrates advanced technologies from Midea's AI Research Institute, Central Research Institute, and Alibaba's Damo Academy [1] - The system automates imaging processes, including intelligent positioning, image capture, AI quality control, and automatic detection of common chest diseases, generating structured diagnostic reports seamlessly [1] Group 2: Technological Innovation - The system leverages over 4 million cross-domain chest DR imaging data from Wanliyun, enabling the development of a multimodal diagnostic model that surpasses traditional AI's single-point recognition limitations [1] - It introduces a deep reasoning engine that simulates clinical thought processes, allowing for multi-step logical deductions in complex cases [1] Group 3: Quality and Consistency - The model includes standardized report templates to ensure terminological accuracy and traceability, significantly improving the professionalism and consistency of reports [1] - Continuous integration of diagnostic experiences from imaging and clinical experts into the model allows for iterative upgrades, aligning the system's logic closer to real clinical thinking [1]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 18.40 CNY, based on a 23x PE for 2026 [2][5]. Core Views - The company is experiencing short-term pressure on performance, but its ICL business is showing stable growth. The revenue for the first half of 2025 was 4.94 billion CNY, down 20.6% year-on-year, while the net profit attributable to the parent company was 0.1 billion CNY, down 85.7% year-on-year [10]. - The ICL business structure is being optimized, and the strategic transformation towards IVD is accelerating. The revenue from ICL in the first half of 2025 was 1.63 billion CNY, down 25.6% year-on-year, with a significant improvement in the business structure [10]. - The company is actively pursuing overseas business opportunities and has established a new growth curve through "AI + Data" initiatives. The company has received ISO 15189 and EQA certifications for its Vietnam operations, enhancing its recognition in the local healthcare system [10]. Financial Summary - The company's revenue is projected to be 12.231 billion CNY in 2025, with a slight increase of 0.3% year-on-year. The operating profit is expected to recover significantly to 0.247 billion CNY, reflecting a growth of 892.3% year-on-year [4][12]. - The net profit attributable to the parent company is forecasted to be 0.146 billion CNY in 2025, showing a year-on-year increase of 140.8% [4][12]. - The earnings per share (EPS) is expected to be 0.23 CNY in 2025, with projections of 0.80 CNY and 1.00 CNY for 2026 and 2027, respectively [2][4].